PreprintCase ReportVersion 1Preserved in Portico This version is not peer-reviewed
Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide
Version 1
: Received: 8 July 2020 / Approved: 9 July 2020 / Online: 9 July 2020 (07:54:22 CEST)
Version 2
: Received: 1 August 2020 / Approved: 2 August 2020 / Online: 2 August 2020 (18:16:20 CEST)
How to cite:
Youssef, J.G.; Zahiruddin, F.; Al-Saadi, M.; Yau, S.; Goodarzi, A.; Huang, H.J.; Javitt, J.C. Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide. Preprints2020, 2020070178. https://doi.org/10.20944/preprints202007.0178.v1
Youssef, J.G.; Zahiruddin, F.; Al-Saadi, M.; Yau, S.; Goodarzi, A.; Huang, H.J.; Javitt, J.C. Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide . Preprints 2020, 2020070178. https://doi.org/10.20944/preprints202007.0178.v1
Youssef, J.G.; Zahiruddin, F.; Al-Saadi, M.; Yau, S.; Goodarzi, A.; Huang, H.J.; Javitt, J.C. Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide. Preprints2020, 2020070178. https://doi.org/10.20944/preprints202007.0178.v1
APA Style
Youssef, J.G., Zahiruddin, F., Al-Saadi, M., Yau, S., Goodarzi, A., Huang, H.J., & Javitt, J.C. (2020). Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide<strong> </strong>. Preprints. https://doi.org/10.20944/preprints202007.0178.v1
Chicago/Turabian Style
Youssef, J.G., Howard J. Huang and Jonathan C. Javitt. 2020 "Brief Report: Rapid Clinical Recovery from Critical COVID-19 with Respiratory Failure in a Lung Transplant Patient Treated with Intravenous Vasoactive Intestinal Peptide<strong> </strong>" Preprints. https://doi.org/10.20944/preprints202007.0178.v1
Abstract
RLF-100 (Aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP) has been granted Fast Track Designation by the US FDA for the treatment of Critical COVID-19 with Respiratory Failure. We describe the clinical course of the first patient treated with this investigational medication in an open label manner -- a 54 year old patient suffering antibody-mediated rejection of his double lung transplant who contracted COVID-19 with respiratory failure refractory to all currently available therapies. He received three infusions of RLF-100 under an FDA-approved emergency use IND. Within 24 hours of the third infusion, substantial improvement in oxygen saturation and radiographic improvement in characteristic COVID-19 pneumonitis was noted. He was discharged from intensive care at that point and returned home at 1 week on room air.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
